Updates on Chemotherapy-Induced Nausea and Vomiting Management

Slideshow

This slideshow reviews the latest clinical updates surrounding the management of treatment-associated nausea and vomiting, including recommendations, newly approved agents, and more.

Nausea and vomiting are known unwanted side effects associated with cancer treatment, including chemotherapy. In some cases, chemotherapy-induced nausea and vomiting (CINV) can be debilitating for patients, and prevention is key. These slides provide insight into CINV management, recent drug approvals in this area, and current treatment recommendations.

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Related Content
Findings from the phase 3 CARTITUDE-4 trial support the European approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

European Commission Approves Cilta-cel in R/R Multiple Myeloma

April 24th 2024
Article

Findings from the phase 3 CARTITUDE-4 trial support the European approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers | Image Credit: © freshidea - stock.adobe.com.

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers

April 24th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma

April 23rd 2024
Article

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC

April 23rd 2024
Article

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.